Business Wire

B2BROKER Launches cTrader Support & Maintenance Service

14.2.2025 10:46:00 EET | Business Wire | Press release

Share

B2BROKER, a leading liquidity and technology provider, has expanded its services with a new cTrader support and maintenance solution, complementing its existing MT4 and MT5 service offerings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211557945/en/

B2BROKER, a multi-asset liquidity and technology provider, announces the release of its cTrader support and maintenance service. The cTrader Service offers setup, ongoing maintenance, and comprehensive support for your cTrader server, saving you time and financial resources. (Graphic: Business Wire)

cTrader is a widely used multi-asset FOREX/CFD trading platform. Over 300 brokers use it, and adoption is expected to reach 80%. However, high maintenance costs and lengthy team training—often taking up to six months—can pose challenges for brokers.

B2BROKER’s cTrader service solution provides comprehensive technical support and expert dealing training, enabling brokers to streamline operations, reduce costs, and focus on growth.

Notably, clients with an existing cTrader server can benefit from a comprehensive audit service, including a full review of current settings, optimisation recommendations, and seamless transition preparation for B2BROKER’s maintenance.

Here’s a breakdown of the core features included in B2BROKER’s cTrader service:

  • Platform configurations
  • Server support
  • Settings control
  • Trading conditions changes
  • Symbol sessions modification
  • Logs review

Why Choose B2BROKER’s cTrader Service?

B2BROKER’s cTrader service offers a superior alternative to in-house management, providing brokers with expert support, cost savings, and seamless operations.

With extensive expertise in configuring and customising cTrader, B2BROKER’s specialists ensure faster setup, optimised performance, and reduced training requirements—far exceeding the capabilities of most internal teams. This allows brokers to streamline operations without the burden of additional staffing.

The service is also highly cost-effective, offering a more affordable solution than maintaining a full-time in-house team. Clients benefit from 24/7 support and continuous monitoring, ensuring platform stability and peak performance at all times.

B2BROKER takes full responsibility for server infrastructure, employing proactive measures and automated solutions to maintain system reliability and swiftly resolve any issues, keeping trading operations smooth and uninterrupted.

Other benefits of choosing B2BROKER include:

  • Team of Market Experts: B2BROKER’s team is continuously on track with the most recent cTrader updates and best practices.
  • On-call Systems: Customised support levels with proactive tools that guarantee the quickest resolution to any issue.
  • Risk Management Assistance: B2BROKER offers advanced systems for setting risk limits on trading accounts and provides tailored suggestions to every business needs.
  • Direct Communication: Brokers can enjoy direct communication channels with cTrader managers to efficiently deal with all necessary liaisons.
  • Extended Knowledge Base: Clients can access valuable resources for continuous learning and support, including Zendesk Knowledge Base and a dedicated YouTube channel.
  • Training Services: B2BROKER’s team will train the client’s technicians in all aspects of platform customisation and remain available for consultations.

One Solution That Suits All Business Models

B2BROKER recognises that every trading business has unique requirements. Therefore, whether a broker operates independently with cTrader technology or as a standalone entity, B2BROKER offers flexible service plans tailored to diverse business models, ensuring optimised performance and expert support.

“We’ve been in the trading technology field for over a decade, growing alongside our partners at Spotware, the creators of cTrader. We were among the first to launch a cTrader white label solution, and we've recently added a cTrader prop trading white label solution to our offerings. I'm proud to say that our long-standing relationship with Spotware's excellent team enables us to guarantee outstanding service.

Let us take care of everything—from the setup to the daily management of your cTrader servers—so you can focus on achieving your business goals with confidence.”

Arthur Azizov, CEO & Founder of B2BROKER

Start with B2BROKER’s Professional cTrader Service

Choosing B2BROKER’s cTrader maintenance offers professional service to the trading platform, allowing brokers to focus on core business activities and ensuring that all operations are managed by comprehensive support and advanced tools.

Learn more about B2BROKER’s cTrader server service here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211557945/en/

Contacts

sales@B2BROKER.com
+44 208 068 8636

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release

The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye